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ARTICLE
Clinical Study
The ProtecT randomised trial cost-effectiveness analysis
comparing active monitoring, surgery, or radiotherapy
for prostate cancer
Sian M. Noble 1, Kirsty Garfield1,2, J. Athene Lane1,2, Chris Metcalfe1,2, Michael Davis1, Eleanor I. Walsh1, Richard M. Martin1,3,
Emma L. Turner1, Tim J. Peters1, Joanna C. Thorn1, Malcolm Mason4, Prasad Bollina5, James W. F. Catto6, Alan Doherty7,
Vincent Gnanapragasam8,9, Owen Hughes10, Roger Kockelbergh11, Howard Kynaston4, Alan Paul12, Edgar Paez13, Derek J. Rosario14,
Edward Rowe15, Jon Oxley16, John Staffurth4, David E. Neal17, Freddie C. Hamdy17 and Jenny L. Donovan1
BACKGROUND: There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer.
METHODS: The cost-effectiveness of active monitoring, surgery, and radiotherapy was evaluated within the Prostate Testing for
Cancer and Treatment (ProtecT) randomised controlled trial from a UK NHS perspective at 10 years’ median follow-up. Prostate
cancer resource-use collected from hospital records and trial participants was valued using UK reference-costs. QALYs (quality-
adjusted-life-years) were calculated from patient-reported EQ-5D-3L measurements. Adjusted mean costs, QALYs, and incremental
cost-effectiveness ratios were calculated; cost-effectiveness acceptability curves and sensitivity analyses addressed uncertainty;
subgroup analyses considered age and disease-risk.
RESULTS: Adjusted mean QALYs were similar between groups: 6.89 (active monitoring), 7.09 (radiotherapy), and 6.91 (surgery).
Active monitoring had lower adjusted mean costs (£5913) than radiotherapy (£7361) and surgery (£7519). Radiotherapy was the
most likely (58% probability) cost-effective option at the UK NICE willingness-to-pay threshold (£20,000 per QALY). Subgroup
analyses confirmed radiotherapy was cost-effective for older men and intermediate/high-risk disease groups; active monitoring was
more likely to be the cost-effective option for younger men and low-risk groups.
CONCLUSIONS: Longer follow-up and modelling are required to determine the most cost-effective treatment for localised prostate
cancer over a man’s lifetime.
TRIAL REGISTRATION: Current Controlled Trials number, ISRCTN20141297: http://isrctn.org (14/10/2002); ClinicalTrials.gov number,
NCT02044172: http://www.clinicaltrials.gov (23/01/2014).
British Journal of Cancer (2020) 123:1063–1070; https://doi.org/10.1038/s41416-020-0978-4
BACKGROUND
Treatments recommended for cancer localised within the prostate
gland include radical surgery, radiotherapy, and active monitor-
ing/surveillance, where radical treatment is avoided or delayed
unless/until the cancer shows signs of progression. The ProtecT
randomised treatment trial showed there was no evidence of a
difference in prostate cancer mortality at a median of 10 years’
follow-up between 3D-conformal radiotherapy with neo-adjuvant
androgen deprivation therapy (ADT), radical surgery, and active
monitoring in men with clinically localised prostate cancer.1 Men
randomised to surgery and radiotherapy had half the rate of
prostate cancer progression and metastasis compared with the
active monitoring group, but they experienced greater levels of
treatment side effects, including urinary incontinence, erectile
dysfunction and bowel symptoms.2
In most high- and middle-income countries, healthcare
priorities are considered in the context of treatment effectiveness
and its cost. Of two trials that compared surgery with watchful
waiting,3,4 only the Scandinavian Prostate Cancer Group-4 trial
(SPCG-4), conducted in the pre-PSA (Prostate Specific Antigen) era,
evaluated costs. SPCG-4 found costs 34% higher for surgery
compared with watchful waiting at a median of 12 years’ follow-
up. The higher costs for surgery related to the initial treatment
costs.3 In the absence of more contemporary trial data, models
www.nature.com/bjc
Received: 7 November 2019 Revised: 8 June 2020 Accepted: 25 June 2020
Published online: 16 July 2020
1Bristol Medical School, University of Bristol, Bristol, UK; 2Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK; 3National Institute for Health
Research, Bristol Biomedical Research Centre, University of Bristol, Bristol, UK; 4The School of Medicine, University of Cardiff, Cardiff, UK; 5Department of Urology and Surgery,
Western General Hospital, Edinburgh, UK; 6The Academic Urology Unit, University of Sheffield, Sheffield, UK; 7Department of Urology, Queen Elizabeth Hospital, Birmingham, UK;
8The Academic Urology Group, University of Cambridge, Cambridge, UK; 9Cambridge Urology Translational Research and Clinical Trials Office, Cambridge, UK; 10Department of
Urology, Cardiff and Vale University Health Board, Cardiff, UK; 11Department of Urology, University Hospitals Leicester, Leicester, UK; 12Department of Urology, Leeds Teaching
Hospitals NHS Trust, Leeds, UK; 13Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK; 14Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK;
15Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK; 16Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK and 17Nuffield Department of Surgical
Sciences, University of Oxford, Oxford, UK
Correspondence: Sian M. Noble (s.m.noble@bristol.ac.uk)
© The Author(s) 2020 Published by Springer Nature on behalf of Cancer Research UK
have been developed to estimate cost-effectiveness of treatments
but have produced conflicting results.5–9
This paper presents an individual patient data economic
evaluation of the ProtecT trial in terms of costs to the UK NHS
and Quality-Adjusted-Life-Years (QALYs) at a median of 10 years’
follow-up, the prespecified time point for the primary analysis.1
METHODS
Study design and participants
The ProtecT trial’s design and protocol have been published
elsewhere.1,10 In brief, men in nine UK centres who were
detected and diagnosed with clinically localised prostate cancer
following a programme of population-based PSA testing who
met trial eligibility criteria were randomised to active monitoring
(n= 545), surgery (n= 553), or radiotherapy with neo-adjuvant
ADT (n= 545).
Resource-use data collection, coding, and valuation
A UK NHS perspective was used for the study; hence, health
service resource-use data related to prostate cancer and
treatments were recorded from randomisation until November
2015 (a median of 10 years’ follow-up). Resource-use relating to
initial treatments and subsequent interventions were recorded
onto study-specific proformas. Follow-up inpatient stays, out-
patient, Emergency Department and, from April 2005, primary
care attendances were recorded onto schedules at annual
research nurse appointments with participants and from a hospital
medical records review. To ensure data completeness, treatment
proformas and annual schedules were compared, duplicate data
dropped, and combined sources of data used. The trial database
containing some clinical information was used for validation
purposes. Supplementary Table 1 outlines how the resources were
measured, coded and valued (2014–2015 UK £ prices) and
Supplementary Table 2 outlines how missing resource-use and
EQ-5D-3L (QALY) data were handled.
Outcome measurement
The outcome for the economic analysis is the QALY at a median
of 10 years’ follow-up. As recommended by NICE, utility values
were estimated from the Euroqol EQ-5D-3L questionnaire
and associated societal UK utility tariffs.11 The EQ-5D-3L was
participant-completed prior to diagnosis (baseline), at 6 months,
and annually from each man’s randomisation date. Men who
died were assigned a zero-utility value for the remaining years
they could have been trial participants. Utility values were
combined to estimate the number of QALYs for each participant
using the area-under-the-curve approach.11
Analysis
The analysis compared the three groups as randomised,
considering prostate cancer-related NHS costs in relation to
QALYs for a median of 10 years. Costs and outcomes for the 10-
year median analysis were discounted at 3.5%.12 Analyses were
conducted in Stata 14.1.13 Each item of resource used was
summed for each man and the mean resource-use calculated by
category (e.g. inpatient stays for infection) and trial group, over
the median 10-year period. Each item’s cost was calculated as the
use (e.g. number of GP visits) multiplied by its unit cost and were
summed annually, across time and by resource-use category for
each participant.
Annual adjusted mean costs and QALYs were estimated using
linear regression. The method of ‘seemingly unrelated regressions’
(SUR), which accounts for the correlation between costs and
QALYs, was used to estimate total adjusted mean costs and
QALYs.14 Costs and QALYs were adjusted for study centre, age,
Gleason score (<7, 7, 8–10) and PSA at baseline, in keeping with
the primary outcome analysis. QALYs were also adjusted for
baseline utility.11 Across the three treatment groups, the adjusted
mean costs and QALYs were compared to assess if any of the
treatments were less effective and more expensive than the other
treatments. If that was the case, then incremental cost-
effectiveness ratios (ICERs) would not be estimated in relation to
that treatment.15 Incremental adjusted mean costs and QALYs,
bias-corrected and accelerated confidence intervals (to account
for non-normal distributions), and ICERs were estimated using SUR
and non-parametric bootstrapping (5000 model iterations).
Regression outputs were used to estimate parametrically the
incremental net monetary benefit (iNMB) statistic and associated
confidence intervals at the UK NICE willingness-to-pay threshold
of £20,000 per QALY.12
Cost-effectiveness acceptability curves (CEACs) were generated
to explore sampling uncertainty in the cost-effectiveness esti-
mates,16 presenting the probability that each trial group is the
cost-effective option compared to the other two groups at a range
of monetary values. To calculate the CEACs, individual net
monetary benefit values were calculated at each willingness to
pay per QALY threshold (£0–£100,000 at £1000 intervals). At each
threshold, 5000 bootstrap model iterations of the adjusted linear
regression models of the net monetary benefits were performed.
The proportion of times (that is the probability) that each
treatment group had the highest net monetary benefit at each
threshold was then calculated and plotted to create the CEAC.
One-way and scenario sensitivity analyses were used to account
for methodological uncertainty or assumptions made during the
study and analysis (see Supplementary Information). Exploratory
subgroup analyses explored heterogeneity within the study
population for age (<65 vs. 65+ years at randomisation); Grade
group (1 vs. 2 and higher; and D’Amico risk classification (low vs.
intermediate and high).17 These were chosen to reflect more
relevant contemporary classifications of the prespecified sub-
groups in the ProtecT primary analysis.1
RESULTS
The adjusted cost and QALY SUR analysis were based on 1101
(67%) of the 1643 men randomised into the ProtecT trial. More
data were available for other analyses (see Table 1, Supplementary
Tables 3–4 for sample sizes).
Resource-use
Resources related to primary treatments varied by randomised
groups (Table 1), with the radiotherapy group having more
outpatient visits, colonoscopy and sigmoidoscopy procedures,
and fewer inpatient stays. There were more primary care
resources, biopsies, magnetic resonance imaging (MRI) scans,
bone scans, and transurethral resections of the prostate (TURP) in
the active monitoring group, and more infection and urinary
sphincter-related inpatient stays in the surgery group.
Basecase results
Over the median 10 years’ follow-up, the total adjusted mean
costs of the surgery (£7519: 95% CI £7099–£7940) and radio-
therapy (£7361: 95% CI £6938–£7783) groups remained very
similar. Both radical groups were more expensive than the active
monitoring group (£5913: 95% CI £5494–£6332). Year 1 adjusted
mean costs were also similar for surgery (£4898) and radiotherapy
(£4708), but much lower for active monitoring (£1166 (Supple-
mentary Table 3; Fig. 1)).
The total adjusted mean QALYs were similar for all groups—just
slightly higher for those allocated to radiotherapy (7.093 QALYs:
95% CI 6.914–7.273) compared with active monitoring (6.976
QALYs: 95% CI 6.798–7.154) and surgery (6.909 QALYs: 95% CI
6.731–7.087) (Table 2).
The result that the radiotherapy group was more expensive
than the active monitoring group but had slightly higher QALYs
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Table 1. Total unadjusted mean resource-use and cost by allocation arm.
Active monitoring (n= 513)a Radiotherapy (n= 516)a Radical prostatectomy (n= 527)a
Mean number
of unitsb
Mean cost (£) (SD) Mean number
of unitsb
Mean cost (£) (SD) Mean number
of unitsb
Mean cost (£) (SD)
Hospital outpatients visits
Procedure-driven appointments
Protocol radiotherapy 7.77 846 (1608) 28.37 3090 (1665) 3.69 402 (1190)
Non-protocol radiotherapy 1.01 133 (631) 0.37 49 (377) 1.86 245 (835)
CT scan 0.29 26 (53) 0.88 81 (56) 0.22 20 (52)
Radiotherapy preparation 0.27 169 (279) 0.80 503 (252) 0.19 122 (249)
TRUS 0.35 19 (33) 0.29 16 (30) 0.29 16 (30)
Trial without a catheter 0.17 24 (57) 0.09 13 (43) 0.53 73 (73)
Bone scan 0.28 56 (176) 0.11 23 (97) 0.13 26 (102)
MRI scan 0.20 27 (59) 0.13 17 (53) 0.11 15 (45)
TRUS-guided biopsy 0.16 35 (83) 0.07 15 (113) 0.04 9 (47)
Chemotherapy 0.04 58 (663) 0.09 145 (1570) 0.03 50 (844)
Other procedures 0.50 60 (250) 0.32 57 (346) 0.34 55 (569)
Speciality-driven appointments
Urology 8.99 868 (787) 9.56 913 (795) 11.64 1122 (810)
Oncology 1.08 156 (463) 2.76 400 (646) 1.31 190 (536)
Uro-oncology 0.62 80 (205) 1.07 137 (235) 0.80 102 (199)
Other specialitiesc 16.56 912 (519) 4.79 374 (577) 3.98 260 (493)
Total outpatient cost 3469 (2754) 5832 (3106) 2707 (2748)
Hospital day case stays
Flexible cystoscopy 0.11 51 (165) 0.06 29 (119) 0.08 35 (142)
Colonoscopy 0.04 21 (126) 0.07 34 (185) 0.02 8 (63)
TWOC 0.04 16 (83) 0.01 2 (29) 0.05 19 (92)
Sigmoidoscopy 0.01 5 (46) 0.04 19 (100) 0.02 7 (81)
Rigid cystoscopy 0.03 27 (160) 0.01 10 (107) 0.04 33 (189)
TRUS-guided biopsy 0.05 25 (117) 0.01 5 (52) 0.01 4 (46)
Education 0.02 10 (70) 0.01 4 (52) 0.02 9 (75)
Chemotherapy 0.01 13 (285) 0.01 21 (390) 0.03 57 (936)
Urodynamics 0.01 2 (25) 0.01 2 (25) 0.02 6 (43)
Brachytherapy 0.01 10 (97) 0.01 6 (75) 0.01 6 (75)
Other day case reasons 0.14 99 (427) 0.12 81 (417) 0.16 119 (505)
Total day case cost 277 (689) 214 (715) 303 (1299)
Hospital inpatient stays
Prostatectomy 0.25 1332 (2380) 0.11 578 (1709) 0.77 4013 (2347)
Infection 0.02 31 (278) 0.02 42 (721) 0.04 76 (509)
TURP 0.05 142 (667) 0.02 44 (333) 0.00 21 (379)
Brachytherapy 0.03 61 (347) 0.02 32 (240) 0.02 31 (237)
Bladder neck procedure 0.01 18 (213) 0.01 30 (278) 0.02 44 (443)
Insertion of urinary sphincter 0.01 129 (1238) 0.01 70 (796) 0.02 206 (1464)
Pain 0.01 17 (243) 0.01 10 (115) 0.02 28 (323)
Urinary retention 0.01 17 (143) 0.01 7 (94) 0.01 14 (131)
Rigid cystoscopy 0.00 3 (60) 0.01 19 (158) 0.01 16 (168)
Blood transfusion 0.02 18 (255) 0.00 0 (0) 0.00 4 (90)
Other inpatient stays 0.15 434 (2298) 0.08 235 (1458) 0.18 403 (2316)
Total inpatient cost 2202 (3956) 1068 (2854) 4855 (4055)
GP practice visits
By healthcare professional
GP 0.81 36 (79) 0.93 41 (86) 1.09 48 (92)
GP nurse 0.91 13 (38) 0.66 10 (34) 0.69 10 (36)
Other 0.05 1 (5) 0.07 1 (9) 0.12 2 (16)
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meant that it was appropriate to estimate an ICER. The ICER of
£12,310 per QALY showed that radiotherapy was the cost-effective
option at the standard UK NICE willingness-to-pay threshold of
£20,000 per QALY. The CEAC (Fig. 2), reflecting sample uncertainty,
shows at this threshold the probability that radiotherapy is the
cost-effective option is 58%, with a probability of 32% for active
monitoring and 10% for surgery.
Sensitivity analyses
Sensitivity analyses (Supplementary Table 5) confirmed these
results for the most part, except when QALY data were not
imputed, or when only including participants following the
introduction of primary care data collection, or excluding men
recruited during the feasibility period; and the scenario using
newer techniques (robotic surgery and intensity-modulated
radiation therapy (IMRT)). In these four analyses, radiotherapy
would be cost-effective at the higher UK-NICE willingness-to-pay
threshold of £30,000 per QALY.
Subgroup analyses
Subgroup analyses (Table 3) showed that QALYs were again
similar between groups, but costs varied. For example, for younger
men and those with lower risk disease (D’Amico classification),
active monitoring was less costly and had higher QALYs than the
radical groups and so was most likely to be the cost-effective
option. However, for older men and those with higher risk disease,
radiotherapy was most likely to be the cost-effective option. At the
£20,000 per QALY threshold, the probability that active monitor-
ing was the cost-effective option was 80% for younger men, 84%
for D’Amico low-risk disease, and 66% for Grade group 1; and that
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Fig. 1 Line charts displaying for each annual follow-up time point, by allocation arm (Active monitoring, Radiotherapy, Radical prostatectomy)
the (a) mean adjusted annual costs and (b) mean adjusted annual QALYs (see Supplementary Tables 3 and 4 for sample sizes).
Table 1 continued
Active monitoring (n= 513)a Radiotherapy (n= 516)a Radical prostatectomy (n= 527)a
Mean number
of unitsb
Mean cost (£) (SD) Mean number
of unitsb
Mean cost (£) (SD) Mean number
of unitsb
Mean cost (£) (SD)
By reason
PSA test 27.41 435 (142) 20.91 332 (140) 20.80 330 (138)
Hormone delivery 1.97 44 (146) 4.24 94 (87) 0.85 19 (87)
Total GP practice cost 528 (243) 477 (205) 409 (231)
Medications
Cyproterone acetate daysd 0.23 1 (5) 0.37 1 (7) 0.16 0 (4)
Hormone injections 2.48 277 (770) 3.96 331 (515) 1.20 154 (606)
Total medication cost 277 (770) 332 (515) 154 (606)
Total cost 6754 (5597) 7923 (4717) 8428 (5636)
aGiven the missing data assumptions (Supplementary Table 2), resource-use was obtained for 1556 (95%) of the 1653 men randomised into the ProtecT study.
bUnits refer as appropriate to: number of outpatient appointments; number of day case visits; number of inpatient stays; number of GP practice visits; number
of medications; number of days.
cIncludes Accident and Emergency visits that did not lead to a procedure costed by the HRG.
dAssuming a daily dose of 200 mg.
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radiotherapy was the cost-effective option was 73% for older men,
69% for D’Amico intermediate/high-risk disease, and 75% for
Grade group 2 or higher.
DISCUSSION
In this cost-effectiveness analysis of the ProtecT treatment trial,
there were remarkably small differences between the treatment
groups at a median of 10 years. Overall, radiotherapy had the
greatest probability of being the cost-effective option for localised
prostate cancer at a median of 10 years follow-up at the UK NICE
willingness-to-pay threshold of £20,000 per QALY and was most
likely to be the cost-effective option at all higher thresholds.
The marginally higher QALYs in the radiotherapy group meant
that although it was more costly than the active monitoring
group, it was more likely to be the cost-effective option. While the
subgroup analyses for both the higher risk, and 65 years and older
groups mirrored these results with greater certainty, for younger
men and/or those with low-risk disease (defined by the D’Amico
classification) active monitoring was more likely to be the cost-
effective treatment group.
Over the median 10-year period, the mean cost-difference
between the radiotherapy and surgery groups was only £159. The
higher surgery group cost was robust to all but the sensitivity
analysis that costed robotic surgery and intensity-modulated
radiotherapy, and in the subgroup analyses it was lower for
younger men and the low-risk groups (range: £127–£244).
Throughout all the analyses the surgery group had fewer QALYs
than the radiotherapy group; the difference in QALYs would
translate into a reduction of 67 days in the best imaginable health
over a median of 10 years.
The finding that the active monitoring group had the lowest
costs may address clinician concern that active surveillance could
be more expensive in the long term because of the need to keep
monitoring patients who might ultimately end up having
treatment. This study shows that at a median 10 years this was
not the case.
The uncertainty reflected in only a 58% probability that the
radiotherapy group was the cost-effective option needs to be
acknowledged; the result indicates that it is inconclusive as to
which treatment over the median 10 years would be the best
value for money. For older men and/or those with higher risk
disease, there was more certainty that the radiotherapy group was
the cost-effective option; similarly, there was more certainty thatT
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Table 3. Subgroup cost-effectiveness results.
Allocation arm na Adjusted costs (£)
Mean (95% CI)
Adjusted QALYs Mean
(95% CI)
Comparison Incremental cost (£)
(95% CI)b
Incremental QALY (95% CI)b ICERc (£/QALY) Incremental NMB (£) at
£20,000/ QALY (95% CI)
Age group 1: Younger—under 65 years old at randomisationd
Active monitoring (AM) 229 6030 (5534−6526) 7.175 (6.945−7.404)
Radical prostatectomy (RP) 232 7458 (6966−7950) 6.933 (6.706−7.160) RP vs. AM 1428 (759−2114) −0.241 (−0.571 to 0.085) AM dominatese RP −6257 (−12,763 to 250)
Radiotherapy (RT) 223 7585 (7083−8087) 7.095 (6.863−7.327) RT vs. AM 1555 (841−2345) −0.079 (−0.417 to 0.241) AM dominates RT −3142 (−9719 to 3435)
Age group 2: Older—65 years old and over at randomisationd
Active monitoring (AM) 141 5671 (4927−6415) 6.654 (6.376−6.933)
Radiotherapy (RT) 141 7047 (6304−7789) 7.104 (6.825−7.382) RT vs. AM 1376 (134−2312) 0.449 (0.045−0.875) 3061 7612 (−337 to 15,561)
Radical prostatectomy (RP) 135 7637 (6874−8400) 6.853 (6.568−7.138) RP vs. RT 590 (−349 to 1754) −0.250 (−0.621 to 0.144) RT dominates RP −5599 (−13,665 to 2467)
D’Amico group 1: Lowf
Active monitoring (AM) 217 4833 (4359−5308) 7.060 (6.830−7.290)
Radical prostatectomy (RP) 226 6806 (6344−7268) 6.843 (6.619−7.067) RP vs. AM 1973 (1272−2620) −0.217 (−0.551 to 0.103) AM dominates RP −6314 (−12,772 to 144)
Radiotherapy (RT) 228 7050 (6585−7514) 7.017 (6.792−7.242) RT vs. AM 2216 (1512−2931) −0.043 (−0.381 to 0.267) AM dominates RT −3078 (−9566 to 3410)
D’Amico group 2: Intermediate/highf,g
Active monitoring (AM) 120 7453 (6548−8358) 6.494 (6.194−6.794)
Radiotherapy (RT) 110 7852 (6909−8795) 6.874 (6.561−7.188) RT vs. AM 399 (−1086 to 1560) 0.380 (−0.049 to 0.849) 1049 7209 (−1604 to 16,023)
Radical prostatectomy (RP) 108 8807 (7852−9762) 6.668 (6.352−6.985) RP vs. RT 955 (−267 to 2246) −0.206 (−0.635 to 0.228) RT dominates RP −5079 (−14,131 to 3972)
Grade group 1h
Active monitoring (AM) 275 5287 (4867−5708) 7.132 (6.924−7.340)
Radical prostatectomy (RP) 275 6892 (6472−7312) 6.997 (6.790−7.205) RP vs. AM 1605 (999−2223) −0.135 (−0.453 to 0.163) AM dominates RP −4302 (−10,233 to 1629)
Radiotherapy (RT) 279 7029 (6612−7446) 7.144 (6.938−7.350) RT vs. AM 1742 (1143−2388) 0.012 (−0.288 to 0.303) 146,076 −1503 (−7413 to 4407)
Grade group 2 and higherh,i
Active monitoring (AM) 95 7799 (6694−8904) 6.558 (6.223−6.892)
Radiotherapy (RT) 85 8522 (7359−9685) 6.943 (6.591−7.295) RT vs. AM 723 (−1160 to 2337) 0.385 (−0.108 to 0.905) 1878 6974 (−2819 to 16,767)
Radical prostatectomy (RP) 92 9249 (8130−10,369) 6.598 (6.259−6.937) RP vs. RT 727 (−856 to 2188) −0.345 (−0.797 to 0.132) RT dominates RP −7,625 (−17,445 to 2194)
aIncluding only participants for whom we have complete cost and QALY information.
bBias-corrected and accelerated confidence interval based on 5000 bootstrap replications.
cICERs cannot be estimated directly from the incremental costs and QALYs due to rounding.
dAdjusted for study centre, Gleason score (2–6, 7, 8–10) and PSA at baseline. QALYs were also adjusted for baseline utility.
eDominates means that the treatment is less costly and more effective than the other treatment.
fAdjusted for study centre and age at baseline. QALYs were also adjusted for baseline utility.
g D’Amico group 2, 0.02% of bootstrap replicates failed to converge.
hAdjusted for study centre, age at baseline, and PSA at baseline. QALYs were also adjusted for baseline utility.
iGrade group 2 and higher, 0.7% of bootstrap replicates failed to converge.
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the active monitoring group was the cost-effective option for
younger men and/or those with low-risk disease—although these
findings, being from subgroup analyses were conducted on
smaller numbers and therefore need to be interpreted with some
caution.
This study is the first and only economic evaluation within a
randomised trial comparing the three contemporary major
treatment modalities (ProtecT). The only previous randomised
evidence came from SPCG-4, comparing surgery with watchful
waiting—not active monitoring, and in the pre-PSA era. This
showed higher costs in the surgery arm.3 The findings from this
study are discordant with some modelling studies. To facilitate
comparisons, published costs from the modelling studies were
inflated to 2015 prices18 and converted to relevant currencies
using 2015 purchasing power parities.19 Two lifetime modelling
studies based on 65-year-old men indicated that active surveil-
lance was the most cost-effective strategy compared with radical
prostatectomy (7.6 QALYs: €9585 (£9260 vs. 7.56 QALYs: €16,468
(£15,911)8 and 8.85 QALYs: US$39,894 (£28,796) vs. 7.95 QALYs: US
$38,180 (£27,559)6) and IMRT (8.10 QALYs: US$48,699 (£35,152)6].
In two models using SPCG-4 data, surgery was shown to be cost-
effective, although it was more expensive than watchful waiting
for 65-year-old men (ICER: 58,045 SEK (£4957) per QALY)20 and
when an active surveillance programme was considered (ICER: NZ
$33,160 (£16,070)).9 The limited availability of outcome data has
been acknowledged to have been a weakness of the models
produced.6,8
The main strength of this study is that it is based on individual
patient data from the ProtecT randomised trial comparing the
three contemporary major treatment modalities over a 10-year
median duration. The use of medical records in conjunction with a
participant visit meant that hospital-based missing data were
minimised and likely to be missing completely at random. The
presentation of resources used and their costs, and the use of
different willingness-to-pay per QALY thresholds, means that
country-specific costs and thresholds can be applied to these data.
Limitations of the study include changes that have occurred
during the study’s duration. New techniques such as robot-
assisted surgery and IMRT have become more prevalent and are
potentially more expensive; in addition, there has been a global
shift to shorter treatment courses of radiotherapy. A sensitivity
analysis in which surgery was costed as robot-assisted, and
radiotherapy as intensity-modulated radiotherapy meant that the
radiotherapy group was only cost-effective at the higher £30,000
per QALY threshold; however, reducing the number of fractions
delivered led to the radiotherapy arm becoming more cost-
effective. Active surveillance programmes have also changed over
time. Improved diagnostic techniques (mpMRI) might enable
better selection of patients, which could lead to fewer changing to
radical treatments or developing metastases, potentially lowering
costs and improving effectiveness.
Another important limitation relates to the small number of
events in the ProtecT trial to date because of the long natural
history of prostate cancer, meaning that longer follow-up is
needed to establish whether there are differences in mortality
between the groups—which could change the balance of cost-
effectiveness. In the late 1990s when the ProtecT trial was being
designed, a 10-year time horizon was expected to show
differences in clinical events. The exploratory subgroup analyses
suggested differences in costs and effectiveness between age and
prostate cancer risk groups. It would thus be premature to imply
ruling out any of the treatment options at the present time,
particularly following the 23-year follow-up of the SPCG-4 trial
demonstrating improved survival in men receiving surgery
compared with watchful waiting.21 Longer-term follow-up is
needed in ProtecT to ascertain survival differences.
Other limitations relate to data collection and analysis. Primary
care resource-use was not recorded in the follow-up schedules at
the beginning of the trial. Therefore, all neo-adjuvant ADT
treatment and PSA tests recorded in the trial database were
costed. A sensitivity analysis including only participants with all
primary care visits recorded indicated that the radiotherapy group
was only cost-effective at the higher £30,000 per QALY threshold.
Missing data occurring within the follow-up proformae were
imputed following discussions with clinical staff, and a researcher
blinded to treatment allocation removed duplicated events
between sources, which could have led to small errors. Incomplete
EQ-5D-3L data meant QALYs could only be calculated for 69% of
the sample and could have been missing not at random, for
example due to ill health. There is a suggestion that participants
missing from the surgery group may have been less healthy at
baseline than those missing in the other two arms (Supplementary
Table 6), potentially leading to an overestimate in the mean QALY
reported for the surgery group, but not changing the overall
findings.
CONCLUSION
In the primary economic analysis at a median of 10 years,
radiotherapy was the most likely cost-effective option because of
slightly lower initial costs and slightly more QALYs, but this result
was not conclusive. In subgroup analyses, there was more
certainty that radiotherapy was the cost-effective option for older
men and/or those with intermediate/high-risk disease. Active
monitoring was the least costly option overall, and subgroup
analyses suggested it was the most likely cost-effective option for
younger men and/or those with low-risk disease. This evaluation
provided evidence of the cost-effectiveness of the major primary
treatment modalities for clinically localised prostate cancer over a
median 10-year period. Further follow-up and subsequent
modelling are required to compare other types of treatments,
including different radiotherapy modalities, and to assess the
impact of later stages of progressing disease to establish which
treatment might be most cost-effective over a man’s lifetime. In
the meantime, all treatments should continue to be offered, with
patients, clinicians, and policy-makers using these results in
combination with the evidence from ProtecT in relation to the
trade-offs between disease progression, metastases, and urinary,
sexual and bowel function.
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